Latest Oncosil Medical News

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

OncoSil Medical has launched a Security Purchase Plan offering discounted shares and free options to eligible shareholders, aiming to accelerate commercialization of its pancreatic cancer treatment device.

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.

Oncosil Medical Ltd has announced a significant 400-for-1 security consolidation affecting shares, options, and performance rights, with shareholder approval scheduled for late May 2025.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.